Technavio expects global cancer pain therapeutics market to reach over $7 billion by 2019

Renewable energy

 

Covering: This market research report from Technavio segments the global cancer pain therapeutics market by drug class (opioids, non-steroidal anti-inflammatory drugs, and others) and by geography (APAC, EMEA, and the Americas). Key vendors in this market are BioDelivery Sciences, ProStrakan Group, and Teva Pharmaceuticals.

Technavio’s market research analysts estimate the global cancer pain therapeutics market, to grow at a CAGR of more than 9% between 2015 and 2019. The market is characterized by the launch of new products that specifically treats pain related to cancer. The Americas lead the global market for cancer pain therapeutics, accounting for 47% of the total market share. US is the largest revenue-contributing nation in the region, owing to the rising rate of cancer.

The new market research report from Technavio provides a breakdown and analysis of the cancer pain therapeutics segments by technology.

“Currently, the drugs that are available for reducing pains associated with cancer have a prolonged duration of action and are characterized by undesirable effects like sedation and respiratory distress.  Consequently, this presents an opportunity for the vendors to bring in therapies with fewer side effects and a better efficacy parameter,” says Imran Mushtaq, Industry Manager, Lead Analyst, Healthcare & Lifesciences, Technavio Research.

Non-steroidal anti-inflammatory drugs are the most commonly used drugs to treat cancer pain because of their high efficacy and anti-inflammatory action. These drugs block the production of prostaglandins by inhibiting the cyclooxygenase enzyme and, therefore, reduce the pain at the site of injury.

The leading vendors in the global cancer pain therapeutics market include BioDelivery Sciences, ProStrakan Group, and Teva Pharmaceuticals. This market is highly fragmented and contains numerous competitive small and large vendors. Large vendors like BioDelivery Sciences and ProStrakan Group dominate this market during the forecast period and constantly compete with each other to gain maximum traction in this market.

A more detailed analysis is available in the Technavio report, Global Cancer Pain Therapeutics Market 2015-2019.

We can customize reports by other regions and specific segments upon request.

Other related reports: